Genetic testing for Alzheimer's disease

Peter K. Panegyres, Jack Goldblatt, Ian Walpole, Carmela Connor, Toni Liebeck, Karen Harrop

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Genetic factors are important in the development of Alzheimer's disease (AD). Familial AD can result from rare mutations in some genes. Other genes, such as the apolipoprotein E gene (APOE), operate as risk factors for late- onset sporadic AD. On a background of advances in the genetics of AD we suggest a way in which genetic information may be used in the diagnosis of AD. If there is a positive family history of early-onset dementia and the clinical features suggest AD, patients may be tested for presenilin and amyloid precursor protein gene mutations with appropriate pretest and post- test counselling. Predictive testing should be performed under guidelines developed by the World Federation of Neurology and the Human Genetics Society of Australasia. The usefulness of APOE genotyping as an adjunct to conventional diagnostic tests is unknown; data suggest it has low sensitivity and specificity and may have little predictive value in an individual patient. APOE genotyping should not be performed in asymptomatic individuals, except as part of an ethically approved research project; this recommendation is supported by a number of international consensus statements. APOE testing should not be used as a diagnostic test without adequate pretest and post- test counselling, education and support. APOE testing should not be used as a sole diagnostic test in the work-up of patients with AD. Genetic risk factors other than APOE require validation and should not be used routinely, except as part of an ethically approved research protocol.

Original languageEnglish
Article numberPMID:10844923
Pages (from-to)339-343
Number of pages5
JournalMedical Journal of Australia
Volume172
Issue number7
Publication statusPublished - 3 Apr 2000
Externally publishedYes

Fingerprint

Genetic Testing
Alzheimer Disease
Apolipoproteins E
Genes
Routine Diagnostic Tests
Counseling
Presenilins
Mutation
Inborn Genetic Diseases
Amyloid beta-Protein Precursor
Research
Dementia
Consensus
Guidelines
Education
Sensitivity and Specificity

Cite this

Panegyres, P. K., Goldblatt, J., Walpole, I., Connor, C., Liebeck, T., & Harrop, K. (2000). Genetic testing for Alzheimer's disease. Medical Journal of Australia, 172(7), 339-343. [PMID:10844923].
Panegyres, Peter K. ; Goldblatt, Jack ; Walpole, Ian ; Connor, Carmela ; Liebeck, Toni ; Harrop, Karen. / Genetic testing for Alzheimer's disease. In: Medical Journal of Australia. 2000 ; Vol. 172, No. 7. pp. 339-343.
@article{6d24176825604ceb8dc5a92cda7a4818,
title = "Genetic testing for Alzheimer's disease",
abstract = "Genetic factors are important in the development of Alzheimer's disease (AD). Familial AD can result from rare mutations in some genes. Other genes, such as the apolipoprotein E gene (APOE), operate as risk factors for late- onset sporadic AD. On a background of advances in the genetics of AD we suggest a way in which genetic information may be used in the diagnosis of AD. If there is a positive family history of early-onset dementia and the clinical features suggest AD, patients may be tested for presenilin and amyloid precursor protein gene mutations with appropriate pretest and post- test counselling. Predictive testing should be performed under guidelines developed by the World Federation of Neurology and the Human Genetics Society of Australasia. The usefulness of APOE genotyping as an adjunct to conventional diagnostic tests is unknown; data suggest it has low sensitivity and specificity and may have little predictive value in an individual patient. APOE genotyping should not be performed in asymptomatic individuals, except as part of an ethically approved research project; this recommendation is supported by a number of international consensus statements. APOE testing should not be used as a diagnostic test without adequate pretest and post- test counselling, education and support. APOE testing should not be used as a sole diagnostic test in the work-up of patients with AD. Genetic risk factors other than APOE require validation and should not be used routinely, except as part of an ethically approved research protocol.",
author = "Panegyres, {Peter K.} and Jack Goldblatt and Ian Walpole and Carmela Connor and Toni Liebeck and Karen Harrop",
year = "2000",
month = "4",
day = "3",
language = "English",
volume = "172",
pages = "339--343",
journal = "Medical Journal Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "7",

}

Panegyres, PK, Goldblatt, J, Walpole, I, Connor, C, Liebeck, T & Harrop, K 2000, 'Genetic testing for Alzheimer's disease' Medical Journal of Australia, vol. 172, no. 7, PMID:10844923, pp. 339-343.

Genetic testing for Alzheimer's disease. / Panegyres, Peter K.; Goldblatt, Jack; Walpole, Ian; Connor, Carmela; Liebeck, Toni; Harrop, Karen.

In: Medical Journal of Australia, Vol. 172, No. 7, PMID:10844923, 03.04.2000, p. 339-343.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Genetic testing for Alzheimer's disease

AU - Panegyres, Peter K.

AU - Goldblatt, Jack

AU - Walpole, Ian

AU - Connor, Carmela

AU - Liebeck, Toni

AU - Harrop, Karen

PY - 2000/4/3

Y1 - 2000/4/3

N2 - Genetic factors are important in the development of Alzheimer's disease (AD). Familial AD can result from rare mutations in some genes. Other genes, such as the apolipoprotein E gene (APOE), operate as risk factors for late- onset sporadic AD. On a background of advances in the genetics of AD we suggest a way in which genetic information may be used in the diagnosis of AD. If there is a positive family history of early-onset dementia and the clinical features suggest AD, patients may be tested for presenilin and amyloid precursor protein gene mutations with appropriate pretest and post- test counselling. Predictive testing should be performed under guidelines developed by the World Federation of Neurology and the Human Genetics Society of Australasia. The usefulness of APOE genotyping as an adjunct to conventional diagnostic tests is unknown; data suggest it has low sensitivity and specificity and may have little predictive value in an individual patient. APOE genotyping should not be performed in asymptomatic individuals, except as part of an ethically approved research project; this recommendation is supported by a number of international consensus statements. APOE testing should not be used as a diagnostic test without adequate pretest and post- test counselling, education and support. APOE testing should not be used as a sole diagnostic test in the work-up of patients with AD. Genetic risk factors other than APOE require validation and should not be used routinely, except as part of an ethically approved research protocol.

AB - Genetic factors are important in the development of Alzheimer's disease (AD). Familial AD can result from rare mutations in some genes. Other genes, such as the apolipoprotein E gene (APOE), operate as risk factors for late- onset sporadic AD. On a background of advances in the genetics of AD we suggest a way in which genetic information may be used in the diagnosis of AD. If there is a positive family history of early-onset dementia and the clinical features suggest AD, patients may be tested for presenilin and amyloid precursor protein gene mutations with appropriate pretest and post- test counselling. Predictive testing should be performed under guidelines developed by the World Federation of Neurology and the Human Genetics Society of Australasia. The usefulness of APOE genotyping as an adjunct to conventional diagnostic tests is unknown; data suggest it has low sensitivity and specificity and may have little predictive value in an individual patient. APOE genotyping should not be performed in asymptomatic individuals, except as part of an ethically approved research project; this recommendation is supported by a number of international consensus statements. APOE testing should not be used as a diagnostic test without adequate pretest and post- test counselling, education and support. APOE testing should not be used as a sole diagnostic test in the work-up of patients with AD. Genetic risk factors other than APOE require validation and should not be used routinely, except as part of an ethically approved research protocol.

UR - http://www.scopus.com/inward/record.url?scp=0034599585&partnerID=8YFLogxK

M3 - Review article

VL - 172

SP - 339

EP - 343

JO - Medical Journal Australia

JF - Medical Journal Australia

SN - 0025-729X

IS - 7

M1 - PMID:10844923

ER -

Panegyres PK, Goldblatt J, Walpole I, Connor C, Liebeck T, Harrop K. Genetic testing for Alzheimer's disease. Medical Journal of Australia. 2000 Apr 3;172(7):339-343. PMID:10844923.